GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (OTCPK:HKMPF) » Definitions » Cash, Cash Equivalents, Marketable Securities

Hikma Pharmaceuticals (Hikma Pharmaceuticals) Cash, Cash Equivalents, Marketable Securities : $229 Mil (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Hikma Pharmaceuticals Cash, Cash Equivalents, Marketable Securities?

Hikma Pharmaceuticals's quarterly cash, cash equivalents, marketable securities increased from Dec. 2022 ($292.00 Mil) to Jun. 2023 ($294.00 Mil) but then stayed the same from Jun. 2023 ($294.00 Mil) to Dec. 2023 ($229.00 Mil).

Hikma Pharmaceuticals's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($450.00 Mil) to Dec. 2022 ($292.00 Mil) and declined from Dec. 2022 ($292.00 Mil) to Dec. 2023 ($229.00 Mil).


Hikma Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Hikma Pharmaceuticals's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Chart

Hikma Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 465.00 347.00 450.00 292.00 229.00

Hikma Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 450.00 393.00 292.00 294.00 229.00

Hikma Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Hikma Pharmaceuticals  (OTCPK:HKMPF) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Hikma Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Hikma Pharmaceuticals (Hikma Pharmaceuticals) Business Description

Industry
Traded in Other Exchanges
Address
1 New Burlington Place, London, GBR, W1S 2HR
Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.